Lanly Bioscience
Current position:
Non-human primate model

Diabetes model

Non-human primate model


Evaluate the complications of prediabetes, diabetes and advanced diabetes in a translational medicine platform

Evaluation of efficacy in type 1 and type 2 diabetes

Diabetes is a chronic, continuously progressing and incurable disease that is prevalent worldwide. Ninety percent of diabetic patients have type 2 diabetes, which manifests as hyperglycemia associated with overweight, unhealthy diet, lack of exercise, and aging.


Heterosexual diabetes is often regarded as unexplained diabetes and ignored. The underlying pathological mechanism may involve autoimmune diseases destroying beta cells that produce insulin in the pancreatic islets.


Current hypoglycemic treatments have significant side effects, so there is an urgent need for new treatments with lower risks and control of diabetes complications. At the same time, there is an urgent need for suitable technologies and models that can enhance the preclinical evaluation of new drugs for patients.



In spontaneously diabetic non-human primates (NHPs), a drop in glucose disposal index was detected using the hyperglycemic clamp test


Unique highly transformable rodent and non-human primate model platform

Lanly Bioscience's preclinical cardiovascular and metabolic diseases (CVMD) translational medicine technology platform helps you to promote new anti-diabetic drugs from lead compounds to the clinic. We provide a variety of rodent and non-human primate models of type 1 and type 2 diabetes, including commercialized and our unique models with high conversion ability, as well as key experiments with evaluation of the efficacy of anti-diabetic drugs in vivo The end point of the pharmacodynamic study.


Spontaneous and feed-induced non-human primate models

Non-human primate models are currently animal models of human metabolic syndrome, including diabetes, which have strong predictive ability, and can exhibit various complex symptoms, such as uncontrolled blood sugar, dyslipidemia, and diabetes complications. This is essential for the development of new drugs, because the next generation of anti-diabetic drugs mainly target diabetes-related complications and blood sugar control. Evaluating drugs in such models is of great value for understanding drug efficacy, PK/PD relationships, biomarkers, and possible side effects.


Lanly Bioscience provides the world's largest library of spontaneously diabetic non-human primates, which can reproduce all aspects of human diabetes progression including late complications. In addition, we have also established a feed-induced non-human primate model of type 2 diabetes.



Insulin resistance was observed in the blood glucose clamp experiment of a non-human primate model of spontaneous diabetes


A unique rodent model with a functional hand-speed pathway that can simulate various stages of human disease

Our rodent diabetes model includes commercially available models for comparison with historical data sets:


STZ-induced type 1 diabetes model

Spontaneous type 1 diabetes model (NOD and NRG-Akita mice, BB rats)

ZDF, ZSF-1 Type 2 Diabetes Rat Model

db/db and ob/ob type 2 diabetes mouse models

And a highly transformed polygenic model that is closer to the human situation:


ZDSD rat

FATZO mouse

Comprehensive analysis service platform

The experimental endpoints of the in vivo efficacy experiment of diabetes drugs provided by Lanly Bioscience include:


Insulin measurement (chemiluminescence method, MesoScale Discovery)

Blood glucose measurement (Rodents, NovaBiomedical Stat Strip® Xpress)

Continuous glucose monitoring (DSI telemetry on non-human primates and rodents)

Glucose tolerance and impaired insulin response (GTT or oGTT)

Insulin tolerance test, ITT

Glucose treatment and insulin sensitivity (glucose and insulin clamp)

To discuss your diabetes project needs and experience our professional translational medicine services, please contact us

Scan the QR code to read on your phone

Contact Us

Time of issue:2021-03-22 16:58:53

Address:99 Mengxi Road, Shaxi Town, Taicang City, Jiangsu Province

Time of issue:2021-03-22 17:01:27

Lanly Bioscience
Scan code to browse

Time of issue:2021-03-22 16:00:55

Copyright:Lanly Bioscience Technology (Suzhou) Co., Ltd. | Copyright - 2021 All Rights Reserved.       苏ICP备2021010176号       Powered by

Time of issue:2021-03-22 16:01:26

©Lanly Bioscience Technology (Suzhou) Co., Ltd.
Powered by